Cytokines of the IL-1 family: Recognized targets in chronic inflammation underrated in organ transplantations

Clinical Science

Volumn 131, Issue 17, 2017, Pages 2241-2256

  Striz, Ilja ^a  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1;

ANIMAL; GENETICS; HISTOCOMPATIBILITY; HUMAN; IMMUNOLOGY; INFLAMMATION; MULTIGENE FAMILY; ORGAN TRANSPLANTATION;

ANIMALS; HUMANS; INFLAMMATION; INTERLEUKIN-1; MULTIGENE FAMILY; ORGAN TRANSPLANTATION; TRANSPLANTATION IMMUNOLOGY;

EID: 85027994034     PISSN: 01435221     EISSN: 14708736     Source Type: Journal    
DOI: 10.1042/CS20170098     Document Type: Review

References (174)

1. Gery, I., Gershon, R.K. and Waksman, B.H. (1972) Potentiation of the T-lymphocyte response to mitogens. I. The responding cell. J. Exp. Med. 136, 128-142.
2. Dinarello, C.A. (2015) The history of fever, leukocytic pyrogen and interleukin-1. Temperature (Austin) 2, 8-16.
3. Rosenwasser, L.J., Dinarello, C.A. and Rosenthal, A.S. (1979) Adherent cell function in murine T-lymphocyte antigen recognition. IV. Enhancement of murine T-cell antigen recognition by human leukocytic pyrogen. J. Exp. Med. 150, 709-714.
4. Okamura, H., Tsutsi, H., Komatsu, T., Yutsudo, M., Hakura, A., Tanimoto, T. et al. (1995) Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 378, 88-91.
5. Dinarello, C.A. (2005) An IL-1 family member requires caspase-1 processing and signals through the ST2 receptor. Immunity 23, 461-462.
6. Towne, J.E., Garka, K.E., Renshaw, B.R., Virca, G.D. and Sims, J.E. (2004) Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kappaB and MAPKs. J. Biol. Chem. 279, 13677-13688.
7. Kumar, S., Hanning, C.R., Brigham-Burke, M.R., Rieman, D.J., Lehr, R., Khandekar, S. et al. (2002) Interleukin-1F7B (IL-1H4/IL-1F7) is processed by caspase-1 and mature IL-1F7B binds to the IL-18 receptor but does not induce IFN-gamma production. Cytokine 18, 61-71.
8. Bensen, J.T., Dawson, P.A., Mychaleckyj, J.C. and Bowden, D.W. (2001) Identification of a novel human cytokine gene in the interleukin gene cluster on chromosome 2q12-14. J. Interferon Cytokine Res. 21, 899-904.
9. Dinarello, C., Arend, W., Sims, J., Smith, D., Blumberg, H., O'Neill, L. et al. (2010) IL-1 family nomenclature. Nat. Immunol. 11, 973.
10. van de Veerdonk, F.L. and Netea, M.G. (2013) New insights in the immunobiology of IL-1 family members. Front. Immunol. 4, 167.
11. Andersson, J., Bjork, L., Dinarello, C.A., Towbin, H. and Andersson, U. (1992) Lipopolysaccharide induces human interleukin-1 receptor antagonist and interleukin-1 production in the same cell. Eur. J. Immunol. 22, 2617-2623.
12. Dinarello, C.A. and van der Meer, J.W. (2013) Treating inflammation by blocking interleukin-1 in humans. Semin. Immunol. 25, 469-484.
13. Dinarello, C.A. (2013) Overview of the interleukin-1 family of ligands and receptors. Semin. Immunol. 25, 389-393.
14. Sims, J.E. and Smith, D.E. (2010) The IL-1 family: regulators of immunity. Nat. Rev. Immunol. 10, 89-102.
15. Garlanda, C., Dinarello, C.A. and Mantovani, A. (2013) The interleukin-1 family: back to the future. Immunity 39, 1003-1018.
16. Netea, M.G., van de Veerdonk, F.L., van der Meer, J.W., Dinarello, C.A. and Joosten, L.A. (2015) Inflammasome-independent regulation of IL-1-family cytokines. Annu. Rev. Immunol. 33, 49-77.
17. Boraschi, D. and Tagliabue, A. (2013) The interleukin-1 receptor family. Semin. Immunol. 25, 394-407.
18. Kim, B., Lee, Y., Kim, E., Kwak, A., Ryoo, S., Bae, S.H. et al. (2013) The interleukin-1a precursor is biologically active and is likely a key alarmin in the IL-1 family of cytokines. Front. Immunol. 4, 391.
19. Cohen, I., Rider, P., Carmi, Y., Braiman, A., Dotan, S., White, M.R. et al. (2010) Differential release of chromatin-bound IL-1alpha discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation. Proc. Natl. Acad. Sci. U.S.A. 107, 2574-2579.
20. Yin, Y., Pastrana, J.L., Li, X., Huang, X., Mallilankaraman, K., Choi, E.T. et al. (2013) Inflammasomes: sensors of metabolic stresses for vascular inflammation. Front. Biosci. (Landmark Ed.) 18, 638-649.
21. Dinarello, C.A. and Wolff, S.M. (1982) Molecular basis of fever in humans. Am. J. Med. 72, 799-819.
22. Dinarello, C.A. (2005) Blocking IL-1 in systemic inflammation. J. Exp. Med. 201, 1355-1359.
23. Unden, A.L., Andreasson, A., Elofsson, S., Brismar, K., Mathsson, L., Ronnelid, J. et al. (2007) Inflammatory cytokines, behaviour and age as determinants of self-rated health in women. Clin. Sci. (Lond.) 112, 363-373.
24. Kurt, A.N., Aygun, A.D., Godekmerdan, A., Kurt, A., Dogan, Y. and Yilmaz, E. (2007) Serum IL-1beta, IL-6, IL-8, and TNF-alpha levels in early diagnosis and management of neonatal sepsis. Mediators Inflamm. 2007, 31397.
25. Finckh, A. and Gabay, C. (2008) At the horizon of innovative therapy in rheumatology: new biologic agents. Curr. Opin. Rheumatol. 20, 269-275.
26. Andus, T., Daig, R., Vogl, D., Aschenbrenner, E., Lock, G., Hollerbach, S. et al. (1997) Imbalance of the interleukin 1 system in colonic mucosa-association with intestinal inflammation and interleukin 1 receptor antagonist [corrected] genotype 2. Gut 41, 651-657.
27. Samuels, J. and Ozen, S. (2006) Familial Mediterranean fever and the other autoinflammatory syndromes: evaluation of the patient with recurrent fever. Curr. Opin. Rheumatol. 18, 108-117.
28. Pott Godoy, M.C., Tarelli, R., Ferrari, C.C., Sarchi, M.I. and Pitossi, F.J. (2008) Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease. Brain 131, 1880-1894.
29. Roerink, M.E., van der Schaaf, M.E., Dinarello, C.A., Knoop, H. and van der Meer, J.W. (2017) Interleukin-1 as a mediator of fatigue in disease: a narrative review. J. Neuroinflammation 14, 16.
30. Tilg, H., Mier, J.W., Vogel, W., Aulitzky, W.E., Wiedermann, C.J., Vannier, E. et al. (1993) Induction of circulating IL-1 receptor antagonist by IFN treatment. J. Immunol. 150, 4687-4692.
31. Scotton, C.J., Martinez, F.O., Smelt, M.J., Sironi, M., Locati, M., Mantovani, A. et al. (2005) Transcriptional profiling reveals complex regulation of the monocyte IL-1 beta system by IL-13. J. Immunol. 174, 834-845.
32. Perrier, S., Kherratia, B., Deschaumes, C., Ughetto, S., Kemeny, J.L., Baudet-Pommel, M. et al. (2002) IL-1ra and IL-1 production in human oral mucosal epithelial cells in culture: differential modulation by TGF-beta1 and IL-4. Clin. Exp. Immunol. 127, 53-59.
33. Martel-Pelletier, J., McCollum, R. and Pelletier, J.P. (1993) The synthesis of IL-1 receptor antagonist (IL-1ra) by synovial fibroblasts is markedly increased by the cytokines TNF-alpha and IL-1. Biochim. Biophys. Acta 1175, 302-305.
34. Ortiz, L.A., Dutreil, M., Fattman, C., Pandey, A.C., Torres, G., Go, K. et al. (2007) Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc. Natl. Acad. Sci. U.S.A. 104, 11002-11007.
35. Schmitz, J., Owyang, A., Oldham, E., Song, Y., Murphy, E., McClanahan, T.K. et al. (2005) IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23, 479-490.
36. Kondo, Y., Yoshimoto, T., Yasuda, K., Futatsugi-Yumikura, S., Morimoto, M., Hayashi, N. et al. (2008) Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system. Int. Immunol. 20, 791-800.
37. Allakhverdi, Z., Smith, D.E., Comeau, M.R. and Delespesse, G. (2007) Cutting edge: the ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J. Immunol. 179, 2051-2054.
38. Cherry, W.B., Yoon, J., Bartemes, K.R., Iijima, K. and Kita, H. (2008) A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. J. Allergy Clin. Immunol. 121, 1484-1490.
39. Salmond, R.J., Mirchandani, A.S., Besnard, A.G., Bain, C.C., Thomson, N.C. and Liew, F.Y. (2012) IL-33 induces innate lymphoid cell-mediated airway inflammation by activating mammalian target of rapamycin. J. Allergy Clin. Immunol. 130, 1159-1166.e6.
40. Brabcova, E., Kolesar, L., Thorburn, E. and Striz, I. (2014) Chemokines induced in human respiratory epithelial cells by IL-1 family of cytokines. Folia Biol. (Praha) 60, 180-186.
41. Divekar, R. and Kita, H. (2015) Recent advances in epithelium-derived cytokines (IL-33, IL-25, and thymic stromal lymphopoietin) and allergic inflammation. Curr. Opin. Allergy Clin. Immunol. 15, 98-103.
42. Miller, A.M., Xu, D., Asquith, D.L., Denby, L., Li, Y., Sattar, N. et al. (2008) IL-33 reduces the development of atherosclerosis. J. Exp. Med. 205, 339-346.
43. Kunes, P., Mandak, J., Holubcova, Z., Kolackova, M. and Krejsek, J. (2015) Actual position of interleukin(IL)-33 in atherosclerosis and heart failure: great expectations or en attendant godot? Perfusion 30, 356-374.
44. Kim, J.Y., Lim, S.C., Kim, G., Yun, H.J., Ahn, S.G. and Choi, H.S. (2015) Interleukin-33/ST2 axis promotes epithelial cell transformation and breast tumorigenesis via upregulation of COT activity. Oncogene 34, 4928-4938.
45. Gao, X., Wang, X., Yang, Q., Zhao, X., Wen, W., Li, G. et al. (2015) Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells. J. Immunol. 194, 438-445.
46. Micallef, M.J., Ohtsuki, T., Kohno, K., Tanabe, F., Ushio, S., Namba, M. et al. (1996) Interferon-gamma-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: synergism with interleukin-12 for interferon-gamma production. Eur. J. Immunol. 26, 1647-1651.
47. Hoshino, T., Wiltrout, R.H. and Young, H.A. (1999) IL-18 is a potent coinducer of IL-13 in NK and T cells: a new potential role for IL-18 in modulating the immune response. J. Immunol. 162, 5070-5077.
48. Omoto, Y., Yamanaka, K., Tokime, K., Kitano, S., Kakeda, M., Akeda, T. et al. (2010) Granzyme B is a novel interleukin-18 converting enzyme. J. Dermatol. Sci. 59, 129-135.
49. Tringali, G., Pozzoli, G., Vairano, M., Mores, N., Preziosi, P. and Navarra, P. (2005) Interleukin-18 displays effects opposite to those of interleukin-1 in the regulation of neuroendocrine stress axis. J. Neuroimmunol. 160, 61-67.
50. Shigehara, K., Shijubo, N., Ohmichi, M., Yamada, G., Takahashi, R., Okamura, H. et al. (2000) Increased levels of interleukin-18 in patients with pulmonary sarcoidosis. Am. J. Respir. Crit. Care Med. 162, 1979-1982.
51. Tanaka, H., Miyazaki, N., Oashi, K., Teramoto, S., Shiratori, M., Hashimoto, M. et al. (2001) IL-18 might reflect disease activity in mild and moderate asthma exacerbation. J. Allergy Clin. Immunol. 107, 331-336.
52. Lettesjo, H., Hansson, T., Bergqvist, A., Gronlund, J. and Dannaeus, A. (2005) Enhanced interleukin-18 levels in the peripheral blood of children with coeliac disease. Clin. Exp. Immunol. 139, 138-143.
53. Hultgren, O., Andersson, B., Hahn-Zoric, M. and Almroth, G. (2007) Serum concentration of interleukin-18 is up-regulated in patients with ANCA-associated vasculitis. Autoimmunity 40, 529-531.
54. Altinova, A.E., Yetkin, I., Akbay, E., Bukan, N. and Arslan, M. (2008) Serum IL-18 levels in patients with type 1 diabetes: relations to metabolic control and microvascular complications. Cytokine 42, 217-221.
55. Gangemi, S., Mallamace, A., Minciullo, P.L., Santoro, D., Merendino, R.A., Savica, V. et al. (2002) Involvement of interleukin-18 in patients on maintenance haemodialysis. Am. J. Nephrol. 22, 417-421.
56. Wang, J., Long, Q., Zhang, W. and Chen, N. (2012) Protective effects of exogenous interleukin 18-binding protein in a rat model of acute renal ischemia-reperfusion injury. Shock 37, 333-340.
57. Fujita, K., Ewing, C.M., Isaacs, W.B. and Pavlovich, C.P. (2011) Immunomodulatory IL-18 binding protein is produced by prostate cancer cells and its levels in urine and serum correlate with tumor status. Int. J. Cancer 129, 424-432.
58. Fabbi, M., Carbotti, G. and Ferrini, S. (2015) Context-dependent role of IL-18 in cancer biology and counter-regulation by IL-18BP. J. Leukoc. Biol. 97, 665-675.
59. Nold, M.F., Nold-Petry, C.A., Zepp, J.A., Palmer, B.E., Bufler, P. and Dinarello, C.A. (2010) IL-37 is a fundamental inhibitor of innate immunity. Nat. Immunol. 11, 1014-1022.
60. Xie, Y., Li, Y., Cai, X., Wang, X. and Li, J. (2016) Interleukin-37 suppresses ICAM-1 expression in parallel with NF-κB down-regulation following TLR2 activation of human coronary artery endothelial cells. Int. Immunopharmacol. 38, 26-30.
61. Xia, L., Shen, H. and Lu, J. (2015) Elevated serum and synovial fluid levels of interleukin-37 in patients with rheumatoid arthritis: attenuated the production of inflammatory cytokines. Cytokine 76, 553-557.
62. Song, J., Wu, C., Zhang, X. and Sorokin, L.M. (2013) In vivo processing of CXCL5 (LIX) by matrix metalloproteinase (MMP)-2 and MMP-9 promotes early neutrophil recruitment in IL-1β-induced peritonitis. J. Immunol. 190, 401-410.
63. Zeng, M., Dang, W., Chen, B., Qing, Y., Xie, W., Zhao, M. et al. (2016) IL-37 inhibits the production of pro-inflammatory cytokines in MSU crystal-induced inflammatory response. Clin. Rheumatol. 35, 2251-2258.
64. Li, Y., Wang, Z., Yu, T., Chen, B., Zhang, J., Huang, K. et al. (2014) Increased expression of IL-37 in patients with Graves' disease and its contribution to suppression of proinflammatory cytokines production in peripheral blood mononuclear cells. PLoS ONE 9, e107183.
65. Fonseca-Camarillo, G., Furuzawa-Carballeda, J. and Yamamoto-Furusho, J.K. (2015) Interleukin 35 (IL-35) and IL-37: Intestinal and peripheral expression by T and B regulatory cells in patients with inflammatory bowel disease. Cytokine 75, 389-402.
66. Hojen, J.F., Rasmussen, T.A., Andersen, K.L., Winckelmann, A.A., Laursen, R.R., Gunst, J.D. et al. (2015) Interleukin-37 expression is increased in chronic HIV-1-infected individuals and is associated with inflammation and the size of the total viral reservoir. Mol. Med. 21, 337-345.
67. Huang, Z., Gao, C., Chi, X., Hu, Y.W., Zheng, L., Zeng, T. et al. (2015) IL-37 expression is upregulated in patients with tuberculosis and induces macrophages towards an M2-like phenotype. Scand. J. Immunol. 82, 370-379.
68. Lunding, L., Webering, S., Vock, C., Schroder, A., Raedler, D., Schaub, B. et al. (2015) IL-37 requires IL-18Ralpha and SIGIRR/IL-1R8 to diminish allergic airway inflammation in mice. Allergy 70, 366-373.
69. Charrad, R., Berraies, A., Hamdi, B., Ammar, J., Hamzaoui, K. and Hamzaoui, A. (2016) Anti-inflammatory activity of IL-37 in asthmatic children: correlation with inflammatory cytokines TNF-alpha, IL-beta, IL-6 and IL-17A. Immunobiology 221, 182-187.
70. Ballak, D.B., van Diepen, J.A., Moschen, A.R., Jansen, H.J., Hijmans, A., Groenhof, G.J. et al. (2014) IL-37 protects against obesity-induced inflammation and insulin resistance. Nat. Commun. 5, 4711.
71. Towne, J.E., Renshaw, B.R., Douangpanya, J., Lipsky, B.P., Shen, M., Gabel, C.A. et al. (2011) Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36α, IL-36β, and IL-36γ) or antagonist (IL-36Ra) activity. J. Biol. Chem. 286, 42594-42602.
72. Henry, C.M., Sullivan, G.P., Clancy, D.M., Afonina, I.S., Kulms, D. and Martin, S.J. (2016) Neutrophil-derived proteases escalate inflammation through activation of IL-36 family cytokines. Cell Rep. 14, 708-722.
73. Gabay, C. and Towne, J.E. (2015) Regulation and function of interleukin-36 cytokines in homeostasis and pathological conditions. J. Leukoc. Biol. 97, 645-652.
74. Kolesar, L., Brabcova, E., Thorburn, E., Sekerkova, A., Brabcova, I., Jaresova, M. et al. (2012) Cytokine gene expression profile in monocytic cells after a co-culture with epithelial cells. Immunol. Res. 52, 269-275.
75. Dietrich, D., Martin, P., Flacher, V., Sun, Y., Jarrossay, D., Brembilla, N. et al. (2016) Interleukin-36 potently stimulates human M2 macrophages, Langerhans cells and keratinocytes to produce pro-inflammatory cytokines. Cytokine 84, 88-98.
76. Gunther, S. and Sundberg, E.J. (2014) Molecular determinants of agonist and antagonist signaling through the IL-36 receptor. J. Immunol. 193, 921-930.
77. van de Veerdonk, F.L., Stoeckman, A.K., Wu, G., Boeckermann, A.N., Azam, T., Netea, M.G. et al. (2012) IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist. Proc. Natl. Acad. Sci. U.S.A. 109, 3001-3005.
78. Mora, J., Schlemmer, A., Wittig, I., Richter, F., Putyrski, M., Frank, A.C. et al. (2016) Interleukin-38 is released from apoptotic cells to limit inflammatory macrophage responses. J. Mol. Cell. Biol. 8, 426-438.
79. Ciccia, F., Accardo-Palumbo, A., Alessandro, R., Alessandri, C., Priori, R., Guggino, G. et al. (2015) Interleukin-36alpha axis is modulated in patients with primary Sjogren's syndrome. Clin. Exp. Immunol. 181, 230-238.
80. Nishida, A., Hidaka, K., Kanda, T., Imaeda, H., Shioya, M., Inatomi, O. et al. (2016) Increased expression of interleukin-36, a member of the interleukin-1 cytokine family, in inflammatory bowel disease. Inflamm. Bowel Dis. 22, 303-314.
81. Carrier, Y., Ma, H.L., Ramon, H.E., Napierata, L., Small, C., O'Toole, M. et al. (2011) Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis. J. Invest. Dermatol. 131, 2428-2437.
82. Johnston, A., Xing, X., Guzman, A.M., Riblett, M., Loyd, C.M., Ward, N.L. et al. (2011) IL-1F5, -F6, -F8, and-F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression. J. Immunol. 186, 2613-2622.
83. Frey, S., Derer, A., Messbacher, M.E., Baeten, D.L., Bugatti, S., Montecucco, C. et al. (2013) The novel cytokine interleukin-36alpha is expressed in psoriatic and rheumatoid arthritis synovium. Ann. Rheum. Dis. 72, 1569-1574.
84. Boutet, M.A., Bart, G., Penhoat, M., Amiaud, J., Brulin, B., Charrier, C. et al. (2016) Distinct expression of interleukin (IL)-36alpha, beta and gamma, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn's disease. Clin. Exp. Immunol. 184, 159-173.
85. Wang, M., Wang, B., Ma, Z., Sun, X., Tang, Y., Li, X. et al. (2016) Detection of the novel IL-1 family cytokines by QAH-IL1F-1 assay in rheumatoid arthritis. Cell. Mol. Biol. 62, 31-34.
86. Rudloff, I., Godsell, J., Nold-Petry, C.A., Harris, J., Hoi, A., Morand, E.F. et al. (2015) Brief report: interleukin-38 exerts antiinflammatory functions and is associated with disease activity in systemic lupus erythematosus. Arthritis Rheumatol. 67, 3219-3225.
87. Zhong, Y., Yu, K., Wang, X., Wang, X., Ji, Q. and Zeng, Q. (2015) Elevated plasma IL-38 concentrations in patients with acute ST-segment elevation myocardial infarction and their dynamics after reperfusion treatment. Mediators Inflamm. 2015, 490120.
88. Marrakchi, S., Guigue, P., Renshaw, B.R., Puel, A., Pei, X.Y., Fraitag, S. et al. (2011) Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N. Engl. J. Med. 365, 620-628.
89. Kleiner, G., Marcuzzi, A., Zanin, V., Monasta, L. and Zauli, G. (2013) Cytokine levels in the serum of healthy subjects. Mediators Inflamm. 2013, 434010.
90. Ascon, M., Ascon, D.B., Liu, M., Cheadle, C., Sarkar, C., Racusen, L. et al. (2009) Renal ischemia-reperfusion leads to long term infiltration of activated and effector-memory T lymphocytes. Kidney Int. 75, 526-535.
91. Sadeghi, M., Daniel, V., Naujokat, C., Schmidt, J., Mehrabi, A., Zeier, M. et al. (2010) Decreasing plasma soluble IL-1 receptor antagonist and increasing monocyte activation early post-transplant may be involved in pathogenesis of delayed graft function in renal transplant recipients. Clin. Transplant. 24, 415-423.
92. Thierry, A., Giraud, S., Robin, A., Barra, A., Bridoux, F., Ameteau, V. et al. (2014) The alarmin concept applied to human renal transplantation: evidence for a differential implication of HMGB1 and IL-33. PLoS ONE 9, e88742.
93. Parikh, C.R., Jani, A., Mishra, J., Ma, Q., Kelly, C., Barasch, J. et al. (2006) Urine NGAL and IL-18 are predictive biomarkers for delayed graft function following kidney transplantation. Am. J. Transplant. 6, 1639-1645.
94. Hall, I.E., Yarlagadda, S.G., Coca, S.G., Wang, Z., Doshi, M., Devarajan, P. et al. (2010) IL-18 and urinary NGAL predict dialysis and graft recovery after kidney transplantation. J. Am. Soc. Nephrol. 21, 189-197.
95. Hall, I.E., Doshi, M.D., Reese, P.P., Marcus, R.J., Thiessen-Philbrook, H. and Parikh, C.R. (2012) Association between peritransplant kidney injury biomarkers and 1-year allograft outcomes. Clin. J. Am. Soc. Nephrol. 7, 1224-1233.
96. Yang, Y., Zhang, Z.X., Lian, D., Haig, A., Bhattacharjee, R.N. and Jevnikar, A.M. (2015) IL-37 inhibits IL-18-induced tubular epithelial cell expression of pro-inflammatory cytokines and renal ischemia-reperfusion injury. Kidney Int. 87, 396-408.
97. Foster, A.M., Baliwag, J., Chen, C.S., Guzman, A.M., Stoll, S.W., Gudjonsson, J.E. et al. (2014) IL-36 promotes myeloid cell infiltration, activation, and inflammatory activity in skin. J. Immunol. 192, 6053-6061.
98. Abbate, A. and Dinarello, C.A. (2015) Anti-inflammatory therapies in acute coronary syndromes: is IL-1 blockade a solution? Eur. Heart J. 36, 337-339.
99. Parikh, C.R., Jani, A., Melnikov, V.Y., Faubel, S. and Edelstein, C.L. (2004) Urinary interleukin-18 is a marker of human acute tubular necrosis. Am. J. Kidney Dis. 43, 405-414.
100. Oliveira, J.G., Xavier, P., Sampaio, S.M., Henriques, C., Tavares, I., Mendes, A.A. et al. (2002) Compared to mycophenolate mofetil, rapamycin induces significant changes on growth factors and growth factor receptors in the early days post-kidney transplantation. Transplantation 73, 915-920.
101. Xu, X., Huang, H., Cai, M., Qian, Y., Li, Z., Bai, H. et al. (2013) Combination of IL-1 receptor antagonist, IL-20 and CD40 ligand for the prediction of acute cellular renal allograft rejection. J. Clin. Immunol. 33, 280-287.
102. Manchanda, P.K., Bid, H.K., Kumar, A. and Mittal, R.D. (2006) Genetic association of interleukin-1beta and receptor antagonist (IL-1Ra) gene polymorphism with allograft function in renal transplant patients. Transpl. Immunol. 15, 289-296.
103. Mas, V., Maluf, D., Archer, K., Yanek, K., Mas, L., King, A. et al. (2007) Establishing the molecular pathways involved in chronic allograft nephropathy for testing new noninvasive diagnostic markers. Transplantation 83, 448-457.
104. Mansell, H., Soliman, M., Elmoselhi, H. and Shoker, A. (2015) Elevated circulating interleukin 33 levels in stable renal transplant recipients at high risk for cardiovascular events. PLoS ONE 10, e0142141.
105. Tilg, H., Vogel, W., Aulitzky, W.E., Herold, M., Konigsrainer, A., Margreiter, R. et al. (1990) Evaluation of cytokines and cytokine-induced secondary messages in sera of patients after liver transplantation. Transplantation 49, 1074-1080.
106. Sirota, J.C., Walcher, A., Faubel, S., Jani, A., McFann, K., Devarajan, P. et al. (2013) Urine IL-18, NGAL, IL-8 and serum IL-8 are biomarkers of acute kidney injury following liver transplantation. BMC Nephrol. 14, 17.
107. Sung, W.C., Yu, H.P., Tsai, Y.F., Chung, P.C., Lin, C.C. and Lee, W.C. (2014) The ratio of plasma interleukin-18 is a sensitive biomarker for acute kidney injury after liver transplantation. Transplant. Proc. 46, 816-817.
108. Jin, S.M., Shim, W., Oh, B.J., Oh, S.H., Yu, S.J., Choi, J.M. et al. (2017) Anakinra protects against serum deprivation-induced inflammation and functional derangement in islets isolated from nonhuman primates. Am. J. Transplant. 17, 365-376.
109. Schwarznau, A., Hanson, M.S., Sperger, J.M., Schram, B.R., Danobeitia, J.S., Greenwood, K.K. et al. (2009) IL-1beta receptor blockade protects islets against pro-inflammatory cytokine induced necrosis and apoptosis. J. Cell. Physiol. 220, 341-347.
110. van der Torren, C.R., Verrijn Stuart, A.A., Lee, D., Meerding, J., van de Velde, U., Pipeleers, D. et al. (2016) Serum cytokines as biomarkers in islet cell transplantation for type 1 diabetes. PLoS ONE 11, e0146649.
111. Wu, C.J., Kurbegov, D., Lattin, B., Burchard, E., Finkle, C., Valantine, H. et al. (1994) Cytokine gene expression in human cardiac allograft recipients. Transpl. Immunol. 2, 199-207.
112. Alvarez, C.M., Fernandez, D., Builes, M., Zabaleta, J., Restrepo, L.M., Villegas, A. et al. (2001) Intragraft cytokine expression in heart transplants with mild or no histological rejection. Clin. Transplant. 15, 228-235.
113. Van Hoffen, E., Van Wichen, D., Stuij, I., De Jonge, N., Klopping, C., Lahpor, J. et al. (1996) In situ expression of cytokines in human heart allografts. Am. J. Pathol. 149, 1991-2003.
114. Gu, H., Xie, M., Xu, L., Zheng, X., Yang, Y. and Lv, X. (2015) The protective role of interleukin-18 binding protein in a murine model of cardiac ischemia/reperfusion injury. Transpl. Int. 28, 1436-1444.
115. Striz, I., Brabcova, E., Kolesar, L. and Sekerkova, A. (2014) Cytokine networking of innate immunity cells: a potential target of therapy. Clin. Sci. 126, 593-612.
116. Coccia, M., Harrison, O.J., Schiering, C., Asquith, M.J., Becher, B., Powrie, F. et al. (2012) IL-1beta mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4(+) Th17 cells. J. Exp. Med. 209, 1595-1609.
117. Mateen, S., Zafar, A., Moin, S., Khan, A.Q. and Zubair, S. (2016) Understanding the role of cytokines in the pathogenesis of rheumatoid arthritis. Clin. Chim. Acta 455, 161-171.
118. Cavalli, G. and Dinarello, C.A. (2015) Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. Rheumatology 54, 2134-2144.
119. de Jesus, A.A., Canna, S.W., Liu, Y. and Goldbach-Mansky, R. (2015) Molecular mechanisms in genetically defined autoinflammatory diseases: disorders of amplified danger signaling. Annu. Rev. Immunol. 33, 823-874.
120. Dinarello, C.A. (2014) An expanding role for interleukin-1 blockade from gout to cancer. Mol. Med. 20, S43-S58.
121. Cohen, S., Hurd, E., Cush, J., Schiff, M., Weinblatt, M.E., Moreland, L.W. et al. (2002) Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46, 614-624.
122. Cohen, S.B., Woolley, J.M., Chan, W. and Anakinra 960180 Study Group (2003) Interleukin 1 receptor antagonist anakinra improves functional status in patients with rheumatoid arthritis. J. Rheumatol. 30, 225-231.
123. Bresnihan, B., Newmark, R., Robbins, S. and Genant, H.K. (2004) Effects of anakinra monotherapy on joint damage in patients with rheumatoid arthritis. Extension of a 24-week randomized, placebo-controlled trial. J. Rheumatol. 31, 1103-1111.
124. Scott, I.C., Ibrahim, F., Simpson, G., Kowalczyk, A., White-Alao, B., Hassell, A. et al. (2016) A randomised trial evaluating anakinra in early active rheumatoid arthritis. Clin. Exp. Rheumatol. 34, 88-93.
125. Thaler, K., Chandiramani, D.V., Hansen, R.A. and Gartlehner, G. (2009) Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug Effectiveness Review Project. Biologics 3, 485-498.
126. Ozcakar, Z.B., Ozdel, S., Yilmaz, S., Kurt-Sukur, E.D., Ekim, M. and Yalcinkaya, F. (2016) Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis. Clin. Rheumatol. 35, 441-446.
127. Neel, A., Henry, B., Barbarot, S., Masseau, A., Perrin, F., Bernier, C. et al. (2014) Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzler's syndrome: a French multicenter study. Autoimmun. Rev. 13, 1035-1041.
128. Sonnichsen, A., Saulite, I., Mangana, J., Kerl, K., Mehra, T., Desislava, I. et al. (2016) Interleukin-1 receptor antagonist (anakinra) for Schnitzler syndrome. J. Dermatolog. Treat. 27, 436-438.
129. Schlesinger, N. (2014) Anti-interleukin-1 therapy in the management of gout. Curr. Rheumatol. Rep. 16, 398.
130. Cohen-Aubart, F., Maksud, P., Saadoun, D., Drier, A., Charlotte, F., Cluzel, P. et al. (2016) Variability in the efficacy of the IL1 receptor antagonist anakinra for treating Erdheim-Chester disease. Blood 127, 1509-1512.
131. Van Tassell, B.W., Abouzaki, N.A., Oddi Erdle, C., Carbone, S., Trankle, C.R., Melchior, R.D. et al. (2016) Interleukin-1 blockade in acute decompensated heart failure: a randomized, double-blinded, placebo-controlled pilot study. J. Cardiovasc. Pharmacol. 67, 544-551.
132. Van Tassell, B.W., Buckley, L.F., Carbone, S., Trankle, C.R., Canada, J.M., Dixon, D.L. et al. (2017) Interleukin-1 blockade in heart failure with preserved ejection fraction: rationale and design of the Diastolic Heart Failure Anakinra Response Trial 2 (D-HART2). Clin. Cardiol., doi:10.1002/clc.22719.
133. Urwyler, S.A., Schuetz, P., Ebrahimi, F., Donath, M.Y. and Christ-Crain, M. (2017) Interleukin-1 antagonism decreases cortisol levels in obese individuals. J. Clin. Endocrinol. Metab. 102, 1712-1718.
134. Cabrera, S.M., Wang, X., Chen, Y.G., Jia, S., Kaldunski, M.L., Greenbaum, C.J. et al. (2016) Interleukin-1 antagonism moderates the inflammatory state associated with type 1 diabetes during clinical trials conducted at disease onset. Eur. J. Immunol. 46, 1030-1046.
135. Shakoory, B., Carcillo, J.A., Chatham, W.W., Amdur, R.L., Zhao, H., Dinarello, C.A. et al. (2016) Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial. Crit. Care Med. 44, 275-281.
136. Fleischmann, R.M., Schechtman, J., Bennett, R., Handel, M.L., Burmester, G.R., Tesser, J. et al. (2003) Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial. Arthritis Rheum. 48, 927-934.
137. Lopalco, G., Rigante, D., Giannini, M., Galeazzi, M., Lapadula, G., Iannone, F. et al. (2016) Safety profile of anakinra in the management of rheumatologic, metabolic and autoinflammatory disorders. Clin. Exp. Rheumatol. 34, 531-538.
138. Lopez-Olivo, M.A., Tayar, J.H., Martinez-Lopez, J.A., Pollono, E.N., Cueto, J.P., Gonzales-Crespo, M.R. et al. (2012) Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA 308, 898-908.
139. Taylor, S.A., Vittorio, J.M., Martinez, M., Fester, K.A., Lagana, S.M., Lobritto, S.J. et al. (2016) Anakinra-induced acute liver failure in an adolescent patient with Still's disease. Pharmacotherapy 36, e1-e4.
140. Blech, M., Peter, D., Fischer, P., Bauer, M.M., Hafner, M., Zeeb, M. et al. (2013) One target-two different binding modes: structural insights into gevokizumab and canakinumab interactions to interleukin-1beta. J. Mol. Biol. 425, 94-111.
141. Church, L.D. and McDermott, M.F. (2009) Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders. Curr. Opin. Mol. Ther. 11, 81-89.
142. Ait-Oudhia, S., Lowe, P.J. and Mager, D.E. (2012) Bridging clinical outcomes of canakinumab treatment in patients with rheumatoid arthritis with a population model of IL-1beta kinetics. CPT Pharmacometrics Syst. Pharmacol. 1, e5.
143. Ruperto, N., Quartier, P., Wulffraat, N., Woo, P., Ravelli, A., Mouy, R. et al. (2012) A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum. 64, 557-567.
144. Krause, K., Mahamed, A., Weller, K., Metz, M., Zuberbier, T. and Maurer, M. (2013) Efficacy and safety of canakinumab in urticarial vasculitis: an open-label study. J. Allergy Clin. Immunol. 132, 751-754.e5.
145. Krause, K., Tsianakas, A., Wagner, N., Fischer, J., Weller, K., Metz, M. et al. (2016) Efficacy and safety of canakinumab in Schnitzler syndrome: a multicenter randomized placebo-controlled study. J. Allergy Clin. Immunol. 139, 1311-1320.
146. Laskari, K., Boura, P., Dalekos, G.N., Garyfallos, A., Karokis, D., Pikazis, D. et al. (2017) Longterm beneficial effect of canakinumab in colchicine-resistant familial Mediterranean fever. J. Rheumatol. 44, 102-109.
147. Torene, R., Nirmala, N., Obici, L., Cattalini, M., Tormey, V., Caorsi, R. et al. (2017) Canakinumab reverses overexpression of inflammatory response genes in tumour necrosis factor receptor-associated periodic syndrome. Ann. Rheum. Dis. 76, 303-309.
148. Tarp, S., Amarilyo, G., Foeldvari, I., Christensen, R., Woo, J.M., Cohen, N. et al. (2016) Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials. Rheumatology 55, 669-679.
149. Brachat, A.H., Grom, A.A., Wulffraat, N., Brunner, H.I., Quartier, P., Brik, R. et al. (2017) Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy. Arthr. Res. Ther. 19, 13.
150. Fabiani, C., Vitale, A., Emmi, G., Lopalco, G., Vannozzi, L., Guerriero, S. et al. (2017) Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behcet's disease-related uveitis: a multicenter retrospective observational study. Clin. Rheumatol. 36, 191-197.
151. Ridker, P.M. and Luscher, T.F. (2014) Anti-inflammatory therapies for cardiovascular disease. Eur. Heart. J. 35, 1782-1791.
152. Howard, C., Noe, A., Skerjanec, A., Holzhauer, B., Wernsing, M., Ligueros-Saylan, M. et al. (2014) Safety and tolerability of canakinumab, an IL-1beta inhibitor, in type 2 diabetes mellitus patients: a pooled analysis of three randomised double-blind studies. Cardiovasc. Diabetol. 13, 94.
153. Wulffraat, N.M. (2015) A safety evaluation of canakinumab for the treatment of systemic onset juvenile idiopathic arthritis. Expert Opin. Drug Saf. 14, 1961-1967.
154. Egawa, M., Imai, K., Mori, M., Miyasaka, N. and Kubota, T. (2017) Placental transfer of canakinumab in a patient with Muckle-Wells syndrome. J. Clin. Immunol. 37, 339-341.
155. Issafras, H., Corbin, J.A., Goldfine, I.D. and Roell, M.K. (2014) Detailed mechanistic analysis of gevokizumab, an allosteric anti-IL-1beta antibody with differential receptor-modulating properties. J. Pharmacol. Exp. Ther. 348, 202-215.
156. Cavelti-Weder, C., Babians-Brunner, A., Keller, C., Stahel, M.A., Kurz-Levin, M., Zayed, H. et al. (2012) Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care 35, 1654-1662.
157. Knickelbein, J.E., Tucker, W.R., Bhatt, N., Armbrust, K., Valent, D., Obiyor, D. et al. (2016) Gevokizumab in the treatment of autoimmune non-necrotizing anterior scleritis: results of a phase I/II clinical trial. Am. J. Ophthalmol. 172, 104-110.
158. Tugal-Tutkun, I.M., Kadayifcilar, S.M., Khairallah, M.M., Lee, S.C.M.P., Ozdal, P., Ozyazgan, Y. et al. (2016) Safety and efficacy of gevokizumab in patients with Behcet's disease uveitis: results of an exploratory phase 2 study. Ocul. Immunol. Inflamm. 25, 62-70.
159. McDermott, M.F. (2009) Rilonacept in the treatment of chronic inflammatory disorders. Drugs Today (Barc.) 45, 423-430.
160. Ilowite, N.T., Prather, K., Lokhnygina, Y., Schanberg, L.E., Elder, M., Milojevic, D. et al. (2014) Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 66, 2570-2579.
161. Sundy, J.S., Schumacher, H.R., Kivitz, A., Weinstein, S.P., Wu, R., King-Davis, S. et al. (2014) Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study. J. Rheumatol. 41, 1703-1711.
162. Mitha, E., Schumacher, H.R., Fouche, L., Luo, S.F., Weinstein, S.P., Yancopoulos, G.D. et al. (2013) Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial. Rheumatology 52, 1285-1292.
163. Krause, K., Weller, K., Stefaniak, R., Wittkowski, H., Altrichter, S., Siebenhaar, F. et al. (2012) Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study. Allergy. 67, 943-950.
164. Goldbach-Mansky, R., Shroff, S.D., Wilson, M., Snyder, C., Plehn, S., Barham, B. et al. (2008) A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum. 58, 2432-2442.
165. Hoffman, H.M., Throne, M.L., Amar, N.J., Sebai, M., Kivitz, A.J., Kavanaugh, A. et al. (2008) Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum. 58, 2443-2452.
166. Sloan-Lancaster, J., Abu-Raddad, E., Polzer, J., Miller, J.W., Scherer, J.C., De Gaetano, A. et al. (2013) Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1beta antibody, in patients with type 2 diabetes. Diabetes Care 36, 2239-2246.
167. Bihorel, S., Fiedler-Kelly, J., Ludwig, E., Sloan-Lancaster, J. and Raddad, E. (2014) Population pharmacokinetic modeling of LY2189102 after multiple intravenous and subcutaneous administrations. AAPS J. 16, 1009-1017.
168. Kosloski, M.P., Goss, S., Wang, S.X., Liu, J., Loebbert, R., Medema, J.K. et al. (2016) Pharmacokinetics and tolerability of a dual variable domain immunoglobulin ABT-981 against IL-1alpha and IL-1beta in healthy subjects and patients with osteoarthritis of the knee. J. Clin. Pharmacol. 56, 1582-1590.
169. Hong, D.S., Janku, F., Naing, A., Falchook, G.S., Piha-Paul, S., Wheler, J.J. et al. (2015) Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer. Invest. New Drugs 33, 621-631.
170. El Sayed, H., Kerensky, R., Stecher, M., Mohanty, P. and Davies, M. (2016) A randomized phase II study of Xilonix, a targeted therapy against interleukin 1alpha, for the prevention of superficial femoral artery restenosis after percutaneous revascularization. J. Vasc. Surg. 63, 133-141.e1.
171. Mistry, P., Reid, J., Pouliquen, I., McHugh, S., Abberley, L., DeWall, S. et al. (2014) Safety, tolerability, pharmacokinetics, and pharmacodynamics of single-dose antiinterleukin-18 mAb GSK1070806 in healthy and obese subjects. Int. J. Clin. Pharmacol. Ther. 52, 867-879.
172. McKie, E.A., Reid, J.L., Mistry, P.C., DeWall, S.L., Abberley, L., Ambery, P.D. et al. (2016) A Study to Investigate the efficacy and safety of an anti-interleukin-18 monoclonal antibody in the treatment of type 2 diabetes mellitus. PLoS ONE 11, e0150018.
173. Argiriadi, M.A., Xiang, T., Wu, C., Ghayur, T. and Borhani, D.W. (2009) Unusual water-mediated antigenic recognition of the proinflammatory cytokine interleukin-18. J. Biol. Chem. 284, 24478-24489.
174. Tak, P.P., Bacchi, M. and Bertolino, M. (2006) Pharmacokinetics of IL-18 binding protein in healthy volunteers and subjects with rheumatoid arthritis or plaque psoriasis. Eur. J. Drug Metab. Pharmacokinet. 31, 109-116.